Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

J.M. Smucker Company (NY: SJM )

110.50 +0.30 (+0.28%)
Streaming Delayed Price Updated: 3:52 PM EDT, Apr 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about J.M. Smucker Company

< Previous 1 2 3 4 5 6 7 8 Next >
3 Low-Beta Stocks That Promise Steady Upside Potential
Dive into the stability of low-beta stocks and their potential to shield investors from market upheavals amidst the uncertainty. 
Via InvestorPlace
Top Consumer Staples Aristocrats To Buy Amid Recent Market Volatility
Among the conversation of stocks to consider during the market downturn, there's opportunity brewing on the dividend aristocrats list. The consumer staples sector has heavy representation on the... 
Via Talk Markets
Top 4 Defensive Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Food and Beverage Stocks Look Appetizing After Ozempic Selloff
Investors should brush off Ozempic selloff fears and dive into tasty food and beverage stocks that have been oversold in 2023. 
Via InvestorPlace
Adobe, J.M. Smucker And More On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Liz Young of BNY Mellon Investment Management named Consumer Staples Select Sector SPDR Fund (NYSE: XLP) 
Via Benzinga
J.M. Smucker Bids Farewell To Sahale Snacks: A $34M Deal To Usher In New Growth
J.M. 
Via Benzinga
Analyst Expectations for JM Smucker's Future
Via Benzinga
SJM To Acquire Twinkie Maker TWNK
SJM will pay $30 in cash and $4.25 in stock for the shares and finance it through debt. 
Via Talk Markets
Snacks In The Ozempic Era: Food, Beverage Stocks Crash With Weight Loss Drugs On The Rise
Food and beverage stocks endure their toughest week since May 2022, driven by concerns over weight-loss drugs and shifting consumer behavior. 
Via Benzinga
Big Pharma's Weight Loss Drugs Vs. Snacking Industry: Who Will Prevail?
The rising prevalence of obesity and diabetes drugs like Novo Nordisk A/S's (NYSE: NVO) Wegovy and Ozempic is triggering concerns among investors about the future of the snacking industry.  
Via Benzinga
Ticking Time Bombs: 3 Value Stocks to Dump Before the Damage Is Done
Steer clear of these value stocks whose share prices are being dragged lower by some fundamental problems of the companies they represent. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 112 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 369 companies set new 52-week lows. 
Via Benzinga
M&A Activity: Down But Still Alive
Merger and acquisition activity has slowed, with lingering uncertainty weighing on potential deals. However, M&A activity hasn’t stopped entirely, with news of Cisco Systems stepping up and announcing... 
Via Talk Markets
Peanut Butter and Jelly Twinkies?
The planned acquisition of Hostess Brands by J.M. Smucker is the latest in a series of food mergers. 
Via The Motley Fool
2 Reasons to Like the Smucker-Hostess Deal, One Reason to Hate It
J.M. Smucker recently announced its most significant acquisition in its history. The Smucker-Hostess deal isn’t a slam-dunk win. 
Via InvestorPlace
Betting Big: 7 Blue-Chip Stocks Primed for a Breakout.
Take a position in these leading blue-chip stocks before their share prices reverse course and begin to rise once again. 
Via InvestorPlace
This Analyst With Over 80% Accuracy Rate Sees Around 9% Upside In Smucker - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts
U.S. stocks closed lower on Friday, ahead of the Federal Reserve’s policy meeting this week. The Dow, meanwhile, settled slightly higher last week, while the S&P 500 and Nasdaq both recorded losses for... 
Via Benzinga
Topics Stocks
Exposures US Equities
Top 5 Risk Off Stocks That Are Set To Fly This Month
The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Market Rally Regains Key Level, But Not Decisively; Apple, ARM, Adobe, Oracle In Focus: Weekly Review
The uptrend remains under pressure. 
Via Investor's Business Daily
Why Hostess Brands Stock Jumped This Week
The jams and jelly maker is placing a high value on Hostess Brands' profitable growth. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2023
Via Benzinga
Marathon Oil To Rally Around 70%? Here Are 10 Other Analyst Forecasts For Thursday
Jefferies raised the price target for MetLife, Inc. (NYSE: MET) from $58 to $72. Jefferies analyst Suneet Kamath upgraded the stock from Hold to Buy. MetLife shares fell 0.3% to close at $63.79 on... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2023
Via Benzinga
3 Low-Beta Dividend Stocks to Reduce Portfolio Volatility
During uncertain times, low-beta dividend stocks can offer stability and safety. Plus, these three have attractive yields as well. 
Via InvestorPlace
Oracle, J. M. Smucker And A Tech ETF Up 43% This Year: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Jim Lebenthal of Cerity Partners named Oracle Corporation (NYSE: ORCL) as 
Via Benzinga
Topics ETFs
How To Earn $500 A Month From Smucker Stock After Acquisition News
The J. M. 
Via Benzinga
S&P 500: Tesla, Apple Chipmaker Lead Big Movers
Aerospace giant RTX led losers on the benchmark index Monday. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Nasdaq Rises Over 1%; Hostess Brands Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 1% on Monday. The Dow traded up 0.29% to 34,676.52 while the NASDAQ rose 1.16% to 13,920.60. The S&P... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Avantax Shares Are Trading Higher By Over 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.